Compass Pathways Is Two Weeks From Filing — And 43% Cheaper Than Six Weeks Ago

The NDA, the National Priority Voucher and $444M are all in place; the market has spent the last six weeks voting the other way, and management has quietly stopped talking about approval risk and started talking about CPT codes.

CMPS · Earnings Call · 2026-11-03

Two weeks from the finish line

For three quarters the Compass Pathways story was a regulatory one: rolling submission, advisory committee, REMS certification, filing timelines. On Tuesday it became something else. Kabir Nath opened with the sentence investors have waited years to hear: “We will complete our rolling NDA submission in the next two weeks.” — Kabir Nath, Chief Executive Officer · 2026-11-03 And crucially, the National Priority Voucher isn't decoration — “The voucher sets a one-to-two-month review target for the FDA, so there's the potential for a very rapid approval.” — Kabir Nath, Chief Executive Officer · 2026-11-03 Nath put the median at roughly 60 days, with the company explicitly prepared for a complete approval inside 30-60 days. That is the whole setup: a first-in-class psychedelic, two statistically significant Phase III trials plus a Phase IIb, over 1,000 patients enrolled, and a review clock that runs in weeks rather than the standard ten months. If the tape were grading the probability of approval, this stock would be up. It is not.

The risk migrated from the FDA to the payer

The most telling change this quarter is not in the filing language, it's in the vocabulary. Last December the top-ranked company themes were regulatory: NDA submission, NDA filing, REMS certification, advisory committee. This quarter the fresh, high-momentum keywords are almost entirely commercial-execution: CPT Category III codes, pharmacy benefit, payer access, patient support services, and white glove. The company is behaving like approval is a solved problem and reimbursement is the live one. That shift is well-founded. Lori Englebert's market research is startling: “approximately 90% of interventional psychiatrists stated that they would prescribe COMP360 within the first year of being available. This is the highest willingness to prescribe percentage I have ever seen in pre-launch market research.” — Lori Englebert, Chief Commercial Officer · 2026-11-03 The delivery infrastructure exists — more than 8,500 interventional psychiatry treatment centers, the same rooms and staffing ratios as SPRAVATO, which today reaches fewer than 3% of an estimated 4 million U.S. TRD patients. But the reimbursement plumbing does not yet exist, and Steve Levine was unusually candid about the timeline: “Ultimately, we anticipate that taking 12-18 months” — Steve Levine, Unknown · 2026-11-03 for the CPT codes to move from Category III to Category I. In the interim: patient support programs, coding guidance in the field, and a buy-and-bill/pharmacy-benefit dual channel that Englebert expects to ramp toward SPRAVATO's 30-40% buy-and-bill mix. The federal DEA rescheduling then has to cascade to the states — management notes 93% of the U.S. population lives where state rescheduling is promised within 30 days. That is an enormous amount of operational machinery between an approval letter and a revenue line. Equally, it is more concrete than anything Compass has said before. Three months ago, on the August call, Englebert was still setting expectations that payer negotiations would wait: “we won't start negotiations until we understand the clinical profile better of COMP360.” — François Brisebois, Analyst · 2026-08-05 Now the payer access team is actively engaged across regional, national and state plans.

The thing management will not discuss

Before we turn to Q&A, let me acknowledge that we are aware of the recent speculation regarding another potential filing. There has been no official statement, and we will not be providing any comments on this matter.
Kabir Nath, Chief Executive Officer · 2026-11-03

The dodge is not new. When Sumant Kulkarni asked in May about competitive and legal dynamics versus a rival psilocybin with its own national priority voucher, Nath answered: “I can only comment on the fact that we, Sumant, COMPASS have 2 very large Phase III trials.” — Kabir Nath, Chief Executive Officer · 2026-05-13 Analysts keep asking; management keeps declining. What is different is that the same question now leads the prepared remarks rather than a Q&A answer — a signal that whatever that second filing is, it has become loud enough to be worth pre-empting. For a company whose entire equity value rests on being first to a first-in-class market, a two-player dynamic is the single largest un-modelled variable, and the only defensible moat offered was the patent: the polymorph family runs “to 2038 before patent term restoration, so we anticipate sort of 40, 41-ish probably.” — Kabir Nath, Chief Executive Officer · 2026-11-03

What quietly disappeared

The silence is as informative as the noise. The advisory committee — a live, repeated topic on the November 2025 and May 2026 calls, where Nath insisted “It is the FDA's decision and the FDA's only decision around whether or not to hold an advisory committee” — Kabir Nath, Chief Executive Officer · 2026-05-13 — did not come up once. The National Priority Voucher effectively dissolved that question. Likewise gone from the top of the transcript: suicidal ideation, placebo response, unblinding. For two years those were the bear case; they have simply stopped being the conversation. Even REMS has been demoted from an existential unknown to a training module: Levine now expects roughly one to two hours of REMS training content for prescribers, a far cry from the August framing that “the REMS will not be finalized until we receive approval.” — Lori Englebert, Chief Commercial Officer · 2026-08-05

The tape is voting differently

Here is the tension. Operationally this was the best call in the company's history. The stock is down 43% over 90 trading days, having peaked at $15.19 on September 18 and given back 43.4% of it, against a market cap of roughly $1.1 billion and a whole-history drawdown of 85.5% from the 2020 high of $59.20. Everything is set up for a launch in the first half of 2027, and the equity is behaving like a financing event is coming. The balance sheet says otherwise, at least for now. Management puts $444 million of cash on hand as of September 30 — up from the $384M the second-quarter filing recorded — which Nath says carries the company “well through the launch and into 2028” — Kabir Nath, Chief Executive Officer · 2026-11-03. Runway extends to 10.8 quarters even as R&D holds at $29M a quarter, down 4% year over year. The odd 83.2% liabilities-to-assets ratio and the Q1-to-Q2 income swing are almost certainly warrant and derivative marks, not operational deterioration — but they are the kind of noise that makes a pre-revenue biotech harder to own into a binary catalyst. Which is the real story here: Compass has done the science, done the filing, and is about to do the thing nobody in psychedelic medicine has done — and the market is pricing a 60-day regulatory coin-flip, a CPT code that takes 12-18 months, and a competitor nobody will name. The next two weeks closes the submission; the next two months decides whether the discount was opportunity or warning.